Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AJ9V
|
|||
| Drug Name |
ZW25
|
|||
| Synonyms |
Zanidatamab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Biliary tract cancer [ICD-11: 2C17; ICD-10: C24.9] | Phase 2 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [2] | ||
| Oesophagogastric junction cancer [ICD-11: 2B71.Z] | Phase 2 | [2] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [3], [4] | ||
| Company |
Zymeworks
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04466891) A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.